PHE Scientific Advisor Anupam Jena was recently featured on the award-winning podcast Freakonomics, as part of their “Bad Medicine: The Story of 98.6” 3-part series. Episode one addresses some of the historical mistakes produced by “trial and error” medicine, and asks whether the new era of evidence-based medicine is the solution. Dr. Jena is featured in the first and third episodes of the series.
PHE Senior Research Economist Jason Shafrin presents an interesting picture of the value and pricing of precision medicine, in a new commentary for MedCity News.
Precision Health Economics founders Darius Lakdawalla and Dana Goldman contribute a new commentary for STAT News: “Election Verdict: Pharma Needs a New Prescription.”
Precision for Value’s Dominic Galante and Maureen Hennessey discuss the subject of patient engagement tools with Keith Loria from Medical Economics, and why more physicians aren’t using them.
A biotech company was preparing to launch a new PET imaging agent for prostate cancer patients with suspected biochemical recurrence into the US market. While a high unmet need continued to exist in recurrent prostate cancer, challenges remained in communicating the value of—and gaining reimbursement for—radiochemical imaging agents. This case study shares the approach to a well-structured preliminary pricing strategy to mitigate these challenges and drive success for the product.
At ISPOR’s 19th Annual European Congress, to be held from October 29th – November 2nd, 2016 in Vienna, Austria, Precision will have a very strong presence.
Come visit the Precision team in Booths 1000/900/1001/901!
Precision Health Economics’ senior research economist Jason Shafrin discusses value-based drug pricing and the benefits for payers in HealthcareDIVE.
Dan Renick, President of global market access specialists Precision for Value, explains “the wedge strategy”in a new article for STAT News.
Academic and Industry Leaders Launch Initiative to Advance Value Measurement
Innovation and Value Initiative to apply advanced scientific methodologies and multi-sector leadership to improve value measurement in healthcare
Bethesda, MD, September 28, 2016 – Precision Health Economics today launched the Innovation and Value Initiative (IVI), a multi-stakeholder scientific initiative to advance the way value is measured and rewarded in the healthcare marketplace.
Precision Health Economics’ Scientific Advisor Amitabh Chandra is interviewed on the subject of precision medicine pricing, in a new Q&A for STAT News.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
